Imatinib and docetaxel in combination can effectively inhibit glioma invasion in an in vitro 3D invasion assay

Journal of Neuro-Oncology

Volumn 101, Issue 2, 2011, Pages 189-198

  Kinsella, Paula ^a   Clynes, Martin ^a   Amberger Murphy, Verena ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Docetaxel; Glioma; Imatinib; Invasion; Proliferation

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DOCETAXEL; GLYCOPROTEIN P; IMATINIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PROTEIN EXPRESSION; THREE DIMENSIONAL IMAGING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; HUMANS; INHIBITORY CONCENTRATION 50; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TAXOIDS; TIME FACTORS;

EID: 78651342329     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0246-1     Document Type: Article

References (44)

1. R Stupp, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 10 987 996 1:CAS:528: DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
2. H Ohgaki, et al. 2004 Genetic pathways to glioblastoma: a population-based study Cancer Res 64 19 6892 6899 1:CAS:528:DC%2BD2cXotFalsrc%3D 10.1158/0008-5472.CAN-04-1337 15466178 (Pubitemid 39330996)
3. J Schlessinger 2000 Cell signaling by receptor tyrosine kinases Cell 103 2 211 225 1:CAS:528:DC%2BD3cXns1Cltrs%3D 10.1016/S0092-8674(00)00114-8 11057895
4. P Kleihues, et al. 2002 The WHO classification of tumors of the nervous system J Neuropathol Exp Neurol 61 3 215 225 11895036 discussion 226-9
5. M Hermanson, et al. 1992 Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops Cancer Res 52 11 3213 3219 1:CAS:528:DyaK38Xkt1Cjsbw%3D 1317261
6. B Westermark CH Heldin M Nister 1995 Platelet-derived growth factor in human glioma Glia 15 3 257 263 1:STN:280:DyaK287lslGgsA%3D%3D 10.1002/glia.440150307 8586462
7. DW Sherbenou BJ Druker 2007 Applying the discovery of the Philadelphia chromosome J Clin Invest 117 8 2067 2074 1:CAS:528:DC%2BD2sXoslOgu70%3D 10.1172/JCI31988 17671641 (Pubitemid 47219546)
8. T Kilic, et al. 2000 Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class Cancer Res 60 18 5143 5150 1:CAS:528:DC%2BD3cXntVamur4%3D 11016641
9. B Nagar 2007 c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571) J Nutr 137 6 Suppl 1 1518S 1523S 1:CAS:528: DC%2BD2sXmt1elur4%3D 17513418 discussion 1548S
10. E Raymond, et al. 2008 Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study J Clin Oncol 26 28 4659 4665 1:CAS:528:DC%2BD1cXht1KqtLfL 10.1200/JCO.2008.16.9235 18824712
11. D Katz, et al. 2004 Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor Anticancer Drugs 15 6 599 602 1:CAS:528:DC%2BD2cXkvV2ntb4%3D 10.1097/01.cad.0000132236.38297.a7 15205603 (Pubitemid 38932328)
12. D Hagerstrand, et al. 2006 Characterization of an imatinib-sensitive subset of high-grade human glioma cultures Oncogene 25 35 4913 4922 1:STN:280:DC%2BD28vns1emsQ%3D%3D 10.1038/sj.onc.1209497 16547494 (Pubitemid 44201182)
13. Bissery MC, et al. (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 6(3):339-355, 363-368
14. GL Plosker M Hurst 2001 Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer Pharmacoeconomics 19 11 1111 1134 1:STN:280:DC%2BD3Mnpt1yiug%3D%3D 10.2165/00019053-200119110-00005 11735678
15. M Sanson, et al. 2000 Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study J Neurooncol 50 3 245 249 1:STN:280:DC%2BD3M7mtlOhug%3D%3D 10.1023/A:1006494032052 11263504 (Pubitemid 32192876)
16. P Forsyth, et al. 1996 Phase II trial of docetaxel in patients with recurrent malignant glioma: a study of the National Cancer Institute of Canada Clinical Trials Group Invest New Drugs 14 2 203 206 1:CAS:528:DyaK28XntFClsbg%3D 10.1007/BF00210791 8913841
17. MI Koukourakis, et al. 1999 Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation Int J Radiat Oncol Biol Phys 43 1 107 114 1:CAS:528:DyaK1MXhtFGgsL4%3D 10.1016/S0360-3016(98)00370-8 9989521 (Pubitemid 29065839)
18. P Sampath, et al. 2006 Interstitial docetaxel (Taxotere), carmustine and combined interstitial therapy: a novel treatment for experimental malignant glioma J Neurooncol 80 1 9 17 1:CAS:528:DC%2BD28Xht12qtLrF 10.1007/s11060-006- 9159-4 16636748 (Pubitemid 44473256)
19. M Heenan, et al. 1997 Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance Int J Cancer 71 5 907 915 1:CAS:528:DyaK2sXktlagtb8%3D 10.1002/(SICI)1097-0215(19970529)71:5<907::AID-IJC33>3.0.CO;2-1 9180164 (Pubitemid 27237217)
20. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 1:CAS:528:DyaL2cXktlaksLk%3D 10.1016/0065-2571(84)90007-4 6382953
21. H Towbin T Staehelin J Gordon 1979 Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications Proc Natl Acad Sci USA 76 9 4350 4354 1:CAS:528:DyaE1MXmtVKltLw%3D 10.1073/pnas.76.9.4350 388439
22. D Del Duca T Werbowetski RF Del Maestro 2004 Spheroid preparation from hanging drops: characterization of a model of brain tumor invasion J Neurooncol 67 3 295 303 10.1023/B:NEON.0000024220.07063.70 15164985 (Pubitemid 39137360)
23. T Servidei, et al. 2006 Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation J Cell Physiol 208 1 220 228 1:CAS:528:DC%2BD28XmtVagurY%3D 10.1002/jcp.20659 16575905 (Pubitemid 43849008)
24. G Gucluler Y Baran 2009 Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells Hematology 14 3 139 144 1:CAS:528:DC%2BD1MXptFGlu7s%3D 10.1179/102453309X426164 19490758
25. VR Amberger, et al. 1997 Oligodendrocyte-type 2 astrocyte progenitors use a metalloendoprotease to spread and migrate on CNS myelin Eur J Neurosci 9 1 151 162 1:STN:280:DyaK2s7psFWksA%3D%3D 10.1111/j.1460-9568.1997.tb01363.x 9042579 (Pubitemid 27083485)
26. H Ren, et al. 2009 Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells Basic Clin Pharmacol Toxicol 104 3 241 252 1:CAS:528:DC%2BD1MXivF2rsLc%3D 10.1111/j.1742-7843.2008.00371.x 19159435
27. S Bihorel, et al. 2007 Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier J Neurochem 102 6 1749 1757 1:CAS:528:DC%2BD2sXhtVyksLbN 10.1111/j.1471-4159.2007.04808.x 17696988 (Pubitemid 47329285)
28. P le Coutre, et al. 2004 Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 Cancer Chemother Pharmacol 53 4 313 323 1:CAS:528:DC%2BD2cXisVWhu7s%3D 10.1007/s00280-003-0741-6 14658008 (Pubitemid 38392356)
29. EM Kemper, et al. 2003 Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein Clin Cancer Res 9 7 2849 2855 1:CAS:528:DC%2BD3sXlt1yrsbo%3D 12855665
30. EM Kemper, et al. 2004 Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein Eur J Cancer 40 8 1269 1274 1:CAS:528:DC%2BD2cXjtl2nt7c%3D 10.1016/j.ejca.2004.01.024 15110893 (Pubitemid 38526348)
31. PM Fracasso, et al. 2004 Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies Clin Cancer Res 10 21 7220 7228 1:CAS:528:DC%2BD2cXpsVKltbs%3D 10.1158/1078-0432.CCR-04-0452 15534095 (Pubitemid 39487708)
32. MC Chamberlain 2006 Treatment options for glioblastoma Neurosurg Focus 20 4 E2 E55 10.3171/foc.2006.20.4.12
33. AM Carella, et al. 2010 Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia Leuk Lymphoma 51 2 275 278 1:CAS:528:DC%2BC3cXhtlyrtrw%3D 10.3109/10428190903503446 20038234
34. SH Kim, et al. 2009 Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent Hematol Oncol 27 4 190 197 1:CAS:528:DC%2BC3cXhtVSku7o%3D 10.1002/hon.894 19274615
35. NE Hynes HA Lane 2005 ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 5 341 354 1:CAS:528:DC%2BD2MXjslertb0%3D 10.1038/nrc1609 15864276 (Pubitemid 40637826)
36. AB Heimberger, et al. 2005 Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients Clin Cancer Res 11 4 1462 1466 1:CAS:528:DC%2BD2MXhvVSrsb4%3D 10.1158/1078-0432.CCR-04-1737 15746047 (Pubitemid 40315227)
37. C Haberler, et al. 2006 Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy J Neurooncol 76 2 105 109 1:CAS:528:DC%2BD28Xis1SgsrY%3D 10.1007/s11060-005-4570-9 16205964 (Pubitemid 43125736)
38. R Jiang, et al. 2006 Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays Proteomics 6 10 2964 2971 1:CAS:528:DC%2BD28XlsFagsbc%3D 10.1002/pmic.200500555 16619307 (Pubitemid 43806395)
39. M Stanulla, et al. 1995 Coexpression of stem cell factor and its receptor c-Kit in human malignant glioma cell lines Acta Neuropathol 89 2 158 165 1:CAS:528:DyaK2MXltlansbk%3D 10.1007/BF00296360 7537428
40. LS Steelman, et al. 2004 JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis Leukemia 18 2 189 218 1:CAS:528:DC%2BD2cXlt1ansQ%3D%3D 10.1038/sj.leu.2403241 14737178 (Pubitemid 38240034)
41. T Skorski, et al. 1995 Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells Blood 86 2 726 736 1:CAS:528:DyaK2MXmvVyhu7o%3D 7606002
42. M Mogi, et al. 2003 Akt signaling regulates side population cell phenotype via Bcrp1 translocation J Biol Chem 278 40 39068 39075 1:CAS:528:DC%2BD3sXnslWjtL4%3D 10.1074/jbc.M306362200 12851395 (Pubitemid 37221810)
43. EM Leslie RG Deeley SP Cole 2005 Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense Toxicol Appl Pharmacol 204 3 216 237 1:CAS:528:DC%2BD2MXjsFGqtrY%3D 10.1016/j.taap.2004.10. 012 15845415 (Pubitemid 40552845)
44. MM van den Heuvel-Eibrink, et al. 2007 CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age Ann Hematol 86 5 329 337 1:CAS:528:DC%2BD2sXjt1Kku7Y%3D 10.1007/s00277-007-0269-7 17340137 (Pubitemid 46477296)